FluMist is a live trivalent virus vaccine that uses an attenuated form of the influenza virus to stimulate a protective immune response in the body. It was approved by the FDA in 2003 for active immunization for the prevention of disease caused by influenza A and B viruses in healthy people aged five to 49 years old.
The next generation of FluMist was approved in January 2007 and will be launched in time for the 2007/2008 flu season.
Speaking on behalf of DRC, Paul Kirkconnell, managing director, said: “We are very pleased to be working with an institution like the University of Michigan to purchase a portion of their royalties on the sales of one of the most innovative flu vaccines in the world.”